Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?
Europe
HIV infection
continuum of care
key population
sex
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
31 12 2020
31 12 2020
Historique:
received:
17
12
2019
accepted:
21
08
2020
pubmed:
23
9
2020
medline:
29
4
2021
entrez:
22
9
2020
Statut:
ppublish
Résumé
High uptake of antiretroviral treatment (ART) is essential to reduce human immunodeficiency virus (HIV) transmission and related mortality; however, gaps in care exist. We aimed to construct the continuum of HIV care (CoC) in 2016 in 11 European Union (EU) countries, overall and by key population and sex. To estimate progress toward the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 target, we compared 2016 to 2013 estimates for the same countries, representing 73% of the population in the region. A CoC with the following 4 stages was constructed: number of people living with HIV (PLHIV); proportion of PLHIV diagnosed; proportion of those diagnosed who ever initiated ART; and proportion of those ever treated who achieved viral suppression at their last visit. We estimated that 87% of PLHIV were diagnosed; 92% of those diagnosed had ever initiated ART; and 91% of those ever on ART, or 73% of all PLHIV, were virally suppressed. Corresponding figures for men having sex with men were: 86%, 93%, 93%, 74%; for people who inject drugs: 94%, 88%, 85%, 70%; and for heterosexuals: 86%, 92%, 91%, 72%. The proportion suppressed of all PLHIV ranged from 59% to 86% across countries. The EU is close to the 90-90-90 target and achieved the UNAIDS target of 73% of all PLHIV virally suppressed, significant progress since 2013 when 60% of all PLHIV were virally suppressed. Strengthening of testing programs and treatment support, along with prevention interventions, are needed to achieve HIV epidemic control.
Sections du résumé
BACKGROUND
High uptake of antiretroviral treatment (ART) is essential to reduce human immunodeficiency virus (HIV) transmission and related mortality; however, gaps in care exist. We aimed to construct the continuum of HIV care (CoC) in 2016 in 11 European Union (EU) countries, overall and by key population and sex. To estimate progress toward the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 target, we compared 2016 to 2013 estimates for the same countries, representing 73% of the population in the region.
METHODS
A CoC with the following 4 stages was constructed: number of people living with HIV (PLHIV); proportion of PLHIV diagnosed; proportion of those diagnosed who ever initiated ART; and proportion of those ever treated who achieved viral suppression at their last visit.
RESULTS
We estimated that 87% of PLHIV were diagnosed; 92% of those diagnosed had ever initiated ART; and 91% of those ever on ART, or 73% of all PLHIV, were virally suppressed. Corresponding figures for men having sex with men were: 86%, 93%, 93%, 74%; for people who inject drugs: 94%, 88%, 85%, 70%; and for heterosexuals: 86%, 92%, 91%, 72%. The proportion suppressed of all PLHIV ranged from 59% to 86% across countries.
CONCLUSIONS
The EU is close to the 90-90-90 target and achieved the UNAIDS target of 73% of all PLHIV virally suppressed, significant progress since 2013 when 60% of all PLHIV were virally suppressed. Strengthening of testing programs and treatment support, along with prevention interventions, are needed to achieve HIV epidemic control.
Identifiants
pubmed: 32960957
pii: 5910027
doi: 10.1093/cid/ciaa696
pmc: PMC7778352
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2905-2916Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Int J Epidemiol. 2014 Feb;43(1):235-48
pubmed: 24374889
HIV Med. 2018 May 8;:
pubmed: 29737610
Patient Prefer Adherence. 2019 Apr 03;13:475-490
pubmed: 31040651
J Int AIDS Soc. 2015 Nov 30;18:20634
pubmed: 26626715
AIDS Patient Care STDS. 2018 Oct;32(10):399-407
pubmed: 30277816
Clin Infect Dis. 2018 Mar 19;66(7):1019-1023
pubmed: 29099920
AIDS Behav. 2019 Mar;23(3):557-563
pubmed: 30796638
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
J Acquir Immune Defic Syndr. 2018 Jan 1;77(1):31-40
pubmed: 28961679
Curr Opin HIV AIDS. 2015 Nov;10(6):420-9
pubmed: 26352393
Euro Surveill. 2018 Apr;23(15):
pubmed: 29667577
Lancet HIV. 2017 Nov;4(11):e479-e480
pubmed: 28779854
Addict Sci Clin Pract. 2017 Oct 2;12(1):24
pubmed: 28965489
PLoS One. 2011 Mar 02;6(3):e16986
pubmed: 21399681
Lancet HIV. 2017 Nov;4(11):e475
pubmed: 29096785
AIDS. 2017 Sep 24;31(15):2053-2058
pubmed: 28906276
BMC Public Health. 2016 Jul 12;16:556
pubmed: 27405648
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
AIDS. 2015 Sep 10;29(14):1855-62
pubmed: 26372391
Lancet. 2019 Jun 15;393(10189):2428-2438
pubmed: 31056293
J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):348-355
pubmed: 27351889
Clin Infect Dis. 2017 Jun 15;64(12):1644-1656
pubmed: 28369283
AIDS. 2019 Jan 27;33(1):133-143
pubmed: 30289806
AIDS. 2016 Mar 27;30(6):943-52
pubmed: 26963528
AIDS Care. 2014;26(7):899-906
pubmed: 24279737
HIV Med. 2017 Aug;18(7):490-499
pubmed: 28117527
AIDS. 2006 Jun 26;20(10):1447-50
pubmed: 16791020
Euro Surveill. 2015;20(47):
pubmed: 26624933
J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):112-116
pubmed: 27532476
AIDS. 2018 Sep 24;32(15):2217-2225
pubmed: 30005018
J Acquir Immune Defic Syndr. 2018 Sep 1;79(1):28-37
pubmed: 29847474
AIDS Behav. 2017 Apr;21(4):1016-1024
pubmed: 27752872
Lancet HIV. 2018 Jun;5(6):e301-e308
pubmed: 29893243